Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25186706 | 1.00 | PREP (0.57) | PREPALDH1A1FKBP1ADPP4DPP8 | |
| SCHEMBL3336958 | 1.00 | PREP (0.57) | PREPALDH1A1FKBP1ADPP4DPP8 | |
| SCHEMBL20522842 | 0.96 | FKBP1A (0.54) | PREPALDH1A1FKBP1ADPP4DPP8 | |
| SCHEMBL25174182 | 0.96 | FKBP1A (0.54) | PREPALDH1A1FKBP1ADPP4DPP8 | |
| SCHEMBL28978206 | 0.96 | FKBP1A (0.54) | PREPALDH1A1FKBP1ADPP4DPP8 | |
| SCHEMBL9075684 | 0.88 | HTT (0.54) | PREPALDH1A1DPP4DPP8DPP9 | |
| SCHEMBL9075679 | 0.88 | HTT (0.54) | PREPALDH1A1DPP4DPP8DPP9 | |
| SCHEMBL25174200 | 0.88 | PREP (0.55) | PREPALDH1A1FKBP1ADPP4DPP8 | |
| SCHEMBL3955135 | 0.86 | MEN1 (0.51) | PREPALDH1A1FKBP1ADPP4DPP8 | |
| SCHEMBL4738328 | 0.85 | OPRD1 (0.53) | PREPFKBP1AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1928886-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SmithKline Beecham Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | PREP 1477/4885ALDH1A1 490/4885FKBP1A 1097/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | PREP 4576/4885ALDH1A1 1956/4885FKBP1A 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.